Federated Hermes
JUNO

Federated Hermes’s Juno Therapeutics, Inc. JUNO Stock Holding History

Federated Hermes’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-36,102
Closed -$1.65M – 2299
2017
Q4 		$1.65M Buy
36,102
+12,668
+54% +$632K ﹤0.01% 1010
2017
Q3 		$1.05M Buy
23,434
+4,339
+23% +$148K ﹤0.01% 1189
2017
Q2 		$571K Buy
19,095
+250
+1% +$6.17K ﹤0.01% 1351
2017
Q1 		$418K Sell
18,845
-25,491
-57% -$547K ﹤0.01% 1371
2016
Q4 		$836K Buy
44,336
+14,336
+48% +$351K ﹤0.01% 1183
2016
Q3 		$900K Buy
30,000
+2,386
+9% +$74.2K ﹤0.01% 1126
2016
Q2 		$1.06M Buy
27,614
+18,675
+209% +$775K ﹤0.01% 1082
2016
Q1 		$340K Buy
8,939
+2,848
+47% +$99.2K ﹤0.01% 1383
2015
Q4 		$268K Sell
6,091
-10,000
-62% -$496K ﹤0.01% 1424
2015
Q3 		$655K Buy
16,091
+6,091
+61% +$267K ﹤0.01% 1203
2015
Q2 		$533K Hold
10,000
– – ﹤0.01% 1313
2015
Q1 		$607K Hold
10,000
– – ﹤0.01% 1316
2014
Q4 		$522K Buy
+10,000
New +$448K ﹤0.01% 1339

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Federated Hermes's JUNO Position: Q1 2018 in Review

Federated Hermes sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 36,102 shares — an estimated $1.65M sold.

Federated Hermes first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $1.65M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Federated Hermes reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Federated Hermes sold 36,102 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $1.65M.
  • Federated Hermes first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Federated Hermes's Juno Therapeutics, Inc. position peaked at $1.65M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Federated Hermes's 13F filing for Q1 2018, filed 9 May 2018.